1. Labcorp reports 6.7% revenue growth forecast for 2025. 2. First-quarter total revenue increased by 5.3% compared to last year. 3. Labcorp declared a quarterly dividend of $0.72 per share. 4. Operational cash flow improved to $18.5 million in Q1 2025. 5. Labcorp focuses on expansions in oncology and neurology diagnostics.
Revenue growth and dividend declaration signal solid financial health.
Strong earnings and strategic growth focus will likely enhance investor confidence.
Continued investments in R&D and expansion indicate sustainable growth potential.
BURLINGTON, N.C., April 29, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2025 and updated full-year guidance.
"Labcorp delivered solid performance in the first quarter of 2025," said Adam Schechter, chairman and CEO of Labcorp. "While the macroeconomic environment remains dynamic, the critical nature of the work we do in diagnostics and drug development positions us well for success in 2025 and beyond. We continue to progress our pipeline of attractive acquisitions and partnerships and further expand our test menu in four strategic areas, including oncology, women's health, autoimmune disease and neurology."
In the first quarter, Labcorp advanced its position as a partner of choice for hospitals, health systems and regional/local laboratories.
Labcorp also continued to incorporate the power of science, innovation and advanced technology across the organization during or subsequent to the quarter.
On April 10, 2025, Labcorp announced a quarterly cash dividend of $0.72 per share of common stock, payable on June 11, 2025, to stockholders of record at the close of business on May 29, 2025.
On April 15, 2025, Labcorp issued its 2024 Corporate Responsibility Report. The report demonstrates how the company is pursuing a healthier future as it advances its mission to improve health and improve lives.
| Three Months Ended March 31 | 2025 | 2024 | Delta |
|---|---|---|---|
| Total Revenue | $3.35 | $3.18 | 5.3% |
| Operating Income ("OI") | $326.0 | $321.3 | OI as % of Revenue: 9.7% |
| Net Earnings | $212.8 | $228.0 | - |
Labcorp is updating 2025 full year guidance to reflect its first quarter performance and full year outlook.
2025 Guidance
The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company's operational performance.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions.
This press release contains forward-looking statements, including, but not limited to, statements with respect to various factors affecting the company's businesses.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change.
Source: Labcorp Holdings Inc